Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body™ therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.

Biotechnology

Life Sciences

Therapeutics

Ampersand Biomedicines

Jason Gardner

Daniel Blom

Yann Echelard

Raffi Afeyan

Luciano Rossetti

The Research and Development team at Ampersand Biomedicines focuses on leveraging the company’s advanced AND™ Platform to design and optimize programmable medicines. This interdisciplinary team of scientists and researchers collaborates to identify localizer targets, engineer sophisticated therapeutics, and validate their efficacy in targeting disease sites while sparing healthy tissues. Their work is essential in advancing novel treatment modalities that enhance precision medicine.

Research and Development

Leadership Team

Research and Development

About

Team members

Other teams at Ampersand Biomedicines

Leadership Team